Jubilant Pharmova Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹1,966Cr
- +12.2% YoY
- +3.4% QoQ
- Net profit
- ₹120Cr
- +17.6% YoY
- +17.6% QoQ
- Margin
- 17%
- 0 pp YoY
- +2 pp QoQ
Guidance rank: #73 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Jubilant Pharmova Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables. Q2’FY26 Financials:.
From Jubilant Pharmova Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables.
- H1’FY26 revenue grew by 11% YoY to Rs. 3,867 Cr. across all business units.
- Radiopharmaceuticals Q2’FY26 revenue rose 16% YoY to Rs. 291 Cr.
- Radiopharmacy Q2’FY26 revenue increased 7% YoY to Rs. 607 Cr.
- Allergy Immunotherapy Q2’FY26 revenue increased 14% YoY to Rs. 194 Cr.
- CDMO Sterile Injectables Q2’FY26 revenue rose 30% YoY to Rs. 393 Cr.
- Generics Q2’FY26 revenue fell 3% YoY to Rs. 167 Cr.
- API Q2’FY26 revenue up 8% YoY to Rs. 137 Cr.
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane, USA:
- Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.
- Technology transfer programs ongoing; commercial production expected FY27.
- Line 4 expansion on track; commercial production expected FY28.
- Combined revenue potential for Lines 3 & 4: USD 160-180 million.
- Montreal Facility, Canada:
- Shutdown in Q2’FY26 for quality improvements; restart expected Q3’FY26.
- USD 114 million investment for expansion of sterile fill & lyophilization operations.
- USD 40 million concessional loans from Canadian Government; rest from internal accruals.
- New sterile ophthalmic plant (200-bottle/min) undergoing validation; commercial qualification expected by end FY26.
- Drug Discovery Services:
- Capacity expansion from 1,000 FTEs in FY25 to 4,000 FTEs by FY30.
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,966 | 1,752 | +12.2% | 1,901 | +3.4% |
| Operating profit (EBITDA) | 341 | 289 | +18% | 290 | +17.6% |
| Operating margin | 17% | 17% | 0 pp | 15% | +2 pp |
| Profit before tax | 190 | 144 | +31.9% | 154 | +23.4% |
| Net profit (PAT) | 120 | 102 | +17.6% | 102 | +17.6% |
| EPS (₹) | 7.55 | 6.45 | +17.1% | 6.46 | +16.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.4K Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q2 FY26 results?
Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables. Q2’FY26 Financials:.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane, USA: - Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
